Protego Biopharma closed an oversubscribed $130 million Series B to accelerate PROT‑001, its oral candidate for AL (light‑chain) amyloidosis, into pivotal testing. The financing, led by several life‑science investors, will support IND‑enabling work, scale manufacturing and initiation of a pivotal study in 2026. Protego’s approach—an orally available small molecule designed to stabilize pathogenic light chains—addresses limitations that derailed several antibody programs in this space. Company executives say the modality could offer improved tolerability and chronic administration advantages compared with existing infusion‑based options. Investors view the round as validation of a differentiated mechanism in a rare disease with high unmet need; regulators will scrutinize clinical benefit signals and surrogate biomarker strategies during the pivotal pathway.